| Gene symbol | VEGFA | Synonyms | L-VEGF, MVCD1, VEGF, VPF | Type of gene | protein-coding |
| Chromosome | 6 | Map location | 6p21.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor A | ||||
| GTO ID | GTC1185 |
| Trial ID | NCT00021736 |
| Disease | Choroidal Neovascularization | Macular Degeneration |
| Altered gene | VEGFA |
| Therapeutic/Target gene | Target gene |
| Therapy | Aptamer |
| Treatment | Macugen|pegaptanib|EYE001 |
| Phase | Phase2|Phase3 |
| Recruitment status | Completed |
| Title | Phase II/III Randomized, Double-Masked, Trial, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative AMD). |
| Year | 2001 |
| Country | United States |
| Company sponsor | Eyetech Pharmaceuticals |
| Other ID(s) | EOP1004B |
| Cohort 1 | |||||
|
|||||